MedTrace Logo

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

NCT04705844 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-03-03

No results posted yet for this study

Summary

Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19

Conditions

  • Mild to Moderate COVID-19

Interventions

DRUG

Adalimumab

adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)

DRUG

Placebo

placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)

Sponsors & Collaborators

  • Pharm-Olam, LLC

    collaborator INDUSTRY

  • Chemical, Biological, Radiological, and Nuclear Medical

    collaborator UNKNOWN

  • Alachua Government Services, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-09-30
Completion
2022-09-30
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04705844 on ClinicalTrials.gov